RxDoctor Payments Data

Audrey Ryan

Physician Assistant · Williamsville, NYNPI 1154052777

Payments from drug & device makers

$2,918in general payments, 2019–2025

Across 147 payments — averaging $19.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$455
  • Lilly USA, LLC$319
  • AstraZeneca$215
  • Otsuka America Pharmaceutical, Inc.$212
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$195
  • Alk-abello, Inc$170
  • plus $1K from 22 others

What the payments were for

  • Food & beverage$2,918100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,918 in reported general payments places this provider in the 85th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$6,718
Medicare patients
54
Services billed
129

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban34$34,639
JardianceEmpagliflozin12$21,301
MounjaroTirzepatide18$19,294
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$18,319
OzempicSemaglutide20$15,855
Levothyroxine Sodium84$1,927
Albuterol Sulfate HfaAlbuterol Sulfate52$1,636
Rosuvastatin Calcium87$1,402
Enoxaparin Sodium15$1,369
Naproxen28$1,328
Metoprolol Succinate63$942
Duloxetine Hcl14$837
Atorvastatin Calcium68$816
Lisinopril63$641
Venlafaxine Hcl ErVenlafaxine Hcl15$580

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$68$34,63934 claims
Boehringer IngelheimJardiance$87$21,30112 claims
Lilly USA, LLCMounjaro$319$19,29418 claims
GSKTrelegy Ellipta$34$18,31917 claims
Novo NordiskOzempic$455$15,85520 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →